The approval marks a major advance in targeted treatment for this rare, chronic autoimmune disease, offering twice-yearly maintenance dosing after two initial loading doses
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
Originally established in Punjab, the Vasculitis Society of India is now expanding its footprint nationwide
This product has sales of about US$ 20 million in Europe
Subscribe To Our Newsletter & Stay Updated
